Mette K. Klausen

Copenhagen, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Therapeutic Potential of Incretin-Based Therapies for Alcohol Use Disorder - A narrative review of available clinical evidence.

Therapeutic Potential of Incretin-Based Therapies for Alcohol Use Disorder - A narrative review of available clinical evidence.

Journal: Biological psychiatry

Published: February 06, 2026

Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders: A Randomized Clinical Trial.

Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders: A Randomized Clinical Trial.

Journal: JAMA psychiatry

Published: December 03, 2025

Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial.

Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial.

Journal: Lancet (London, England)

Published: November 13, 2025

Effect of the GLP-1 receptor agonist exenatide on pro-inflammatory and metabolic biomarkers in individuals with alcohol use disorder: Post hoc results from a randomized, double-blinded, placebo-controlled clinical trial.

Effect of the GLP-1 receptor agonist exenatide on pro-inflammatory and metabolic biomarkers in individuals with alcohol use disorder: Post hoc results from a randomized, double-blinded, placebo-controlled clinical trial.

Journal: Alcohol, clinical & experimental research

Published: March 09, 2025

Phosphatidylethanol as an objective measure of heavy drinking days in a clinical trial for alcohol use disorder.

Phosphatidylethanol as an objective measure of heavy drinking days in a clinical trial for alcohol use disorder.

Journal: Alcohol and alcoholism (Oxford, Oxfordshire)

Published: January 30, 2025

Does semaglutide reduce alcohol intake in Danish patients with alcohol use disorder and comorbid obesity? Trial protocol of a randomised, double-blinded, placebo-controlled clinical trial (the SEMALCO trial).

Does semaglutide reduce alcohol intake in Danish patients with alcohol use disorder and comorbid obesity? Trial protocol of a randomised, double-blinded, placebo-controlled clinical trial (the SEMALCO trial).

Journal: BMJ open

Published: January 08, 2025

Blood phosphatidylethanol measurements indicate GLP-1 receptor stimulation causes delayed decreases in alcohol consumption.

Blood phosphatidylethanol measurements indicate GLP-1 receptor stimulation causes delayed decreases in alcohol consumption.

Journal: Alcohol, clinical & experimental research

Published: November 20, 2024

Effects of GLP-1 Receptor Agonists in Alcohol Use Disorder.

Effects of GLP-1 Receptor Agonists in Alcohol Use Disorder.

Journal: Basic & clinical pharmacology & toxicology

Published: August 26, 2024

Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys.

Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys.

Journal: Psychopharmacology

Published: March 12, 2024

GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders.

GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders.

Journal: Nature medicine

Published: November 24, 2023

The LIVER CARE trial - screening for liver disease in individuals attending treatment for alcohol use disorder: a randomized controlled feasibility trial.

The LIVER CARE trial - screening for liver disease in individuals attending treatment for alcohol use disorder: a randomized controlled feasibility trial.

Journal: Pilot and feasibility studies

Published: February 02, 2023

Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial.

Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial.

Journal: JCI insight

Published: March 04, 2022

Showing 1-12 of 16

Last Updated: 09/26/2026